J&J raises 2026 sales and EPS guidance after strong Q2 results

Johnson & Johnson reported second-quarter 2026 results on July 15, 2026, with reported sales growth of 6.6% to $25.3 billion, operational growth of 5.6%, and adjusted operational growth of 5.7%¹. Based on this performance, the company said it increased its 2026 guidance to estimated reported sales of $101.1 billion, or 7.3% growth at the midpoint, and raised its adjusted EPS guidance to $11.68¹, with adjusted operational EPS guidance rising to $11.58, or 7.3% growth at the midpoint¹.

On the regulatory and pipeline side, the release cites several developments during the quarter. These include approvals for "TREMFYA to inhibit the progression of structural joint damage in adults with active psoriatic arthritis," for "CAPLYTA for the prevention of relapse in schizophrenia," and for the "Dual Energy THERMOCOOL SMARTTOUCH SF platform." The company also pointed to new data readouts, including results from "RYBREVANT FASPRO in advanced head and neck cancer," from the combination of "TALVEY plus DARZALEX FASPRO in earlier-line relapsed or refractory multiple myeloma," and from the "OTTAVA" surgical robotics program in upper abdominal procedures, as described in the release's summary of quarterly highlights.

Segment-level sales showed Innovative Medicine worldwide operational sales growing 6.8%, with divestitures negatively impacting growth by 10 basis points¹, driven largely by DARZALEX, CARVYKTI, TECVAYLI and RYBREVANT/LAZCLUZE in Oncology, TREMFYA and Other Immunology in Immunology, and SPRAVATO and CAPLYTA in Neuroscience¹. In MedTech, worldwide operational sales grew 3.6%, with net acquisitions and divestitures negatively impacting growth by 10 basis points¹.

The release also lists a wider set of quarterly regulatory and data announcements, including an FDA priority review for "IMAAVY (nipocalimab-aahu)" in warm autoimmune hemolytic anemia and CHMP backing for a "TECVAYLI" combination in multiple myeloma, alongside the guidance update.